Cyclophosphamide trials for Melanoma

All Cyclophosphamide trials · All Melanoma trials

Phase breakdown

Recruiting trials studying Cyclophosphamide for Melanoma

• A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
  NCT02621021 · Phase: Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 1 location
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
  NCT02830724 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 1 location
• Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
  NCT05296564 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
  NCT04897321 · Phase: Phase 1 · Ages: Up to 21 Years · Sex: All (male and female) · 1 location
• Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
  NCT06961357 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
  NCT07627698 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
  NCT04119024 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
  NCT06771544 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Modified Vaccine for High Risk or Low Residual Melanoma Patients
  NCT01898039 · Phase: Phase 1, Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
  NCT05269381 · Phase: Phase 1, Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
• Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
  NCT06660420 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
  NCT05492682 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
  NCT04282044 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
  NCT06204991 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations

Common questions

How many trials study Cyclophosphamide for Melanoma?

14 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.